China is first country to approve Roche’s C5 inhibitor crovalimab, a subcutaneous option for patients with rare disease PNH.

Novartis has chalked up another clinical trial win for its targeted factor B inhibitor iptacopan as it strives to position the drug as a patient-friendly, oral alternative to big-selling ...